US biotech ipo`s - 500 Beiträge pro Seite

[ohrenschützer]

wer hat lust sich die finger zu verbrennen?

ich schau schon seit ungefähr einem halben jahr auf eine hand voll biotech emmissionen.
sie haben fast alle den selben chart.
emittiert sind sie knapp vor oder nach dem großen einbruch im februar.sie haben also den großen hype noch gar nicht mitgemacht und bei einigen wurde sogar die bookbuildingspanne runtergesetzt.

trotzdem stiegen einige nach der korrektur um mehrere 100%,
vielen dann aber auch in der jüngsten schwächephase im schnitt um 50%. und ein chart gleicht dem anderen.

wie gesagt, einige hat ich schon mal doch halt nur zum falschen zeitpunkt.
ich glaube mann kann, wenn man an genügend infos (verlässlich-kein gepushe) herankommt und die 2-3 guten werte herauspickt eine unglaubliche performenc erziehlen.

bevor ich noch länger um den heisen brei rumrede hier meine liste:

Praecis
Tanox
Intrabiotics
Aclara
Lexicon
Virologic
Orchid
Allos
Paradigm
Sangamo
Exelixis(exel)
Genomic Solution
Sequenom

oder sachen wie pozen:wollten am 28.2 an den markt gehen.listing erfolgte aber erst vor kurzem zum kurs von 15$

und noch viele mehrhst, nenl, dgen, cphd, gnsc,
lsbc, oclx, ista, telk, vers, advm und viele mehr...)
aus mangelnder zeit habe ich mir nun keine genau unter die lupe genommen.doch falls jemand mit einer dieser firmen vertraut ist und sie für unbedingt kaufenswert hällt- dann postet mal.
doch nicht so ein dummfick wie in manchen gnsl (gnsl, das letzte mal unter 30 zu haben-die liegen seit einem viertel jahr darunter-)und pdgm threats.
ich hab zur zeit:
millenium,icos,vertex,medigene,eurofines und such noch ein zwei gewürzmichungen für mein depot.

ciau
ohrenschuetzer
quelle war
Company Name: Applied Molecular Evolution, Inc. Symbol: AMEV Exchange: Nasdaq

Filing Date: May 12, 2000 IPO Date: NA Offering Price : NA
Description: Natural selection doesn`t happen fast enough for Applied Molecular Evolution (AME). Founded in 1989 as Ixsys, the development-stage biotechnology firm improves genes and proteins for medical uses. Employing what AME calls directed evolution, the company adjusts a protein`s amino acids one at a time until the protein
acquires the desired therapuetic characteristics. AME`s biopharmaceuticals have increased the potency of MedImmune`s anti-tumor drug Vitaxin. Bristol-Meyers
Squibb`s AME-improved anti-tumor drug, BR96, has been licensed to Seattle Genetics for further development. Founder, CEO, and president Dr. William Huse (also a
founder of Delphi Ventures) owns about 20% of AME.

Underwriters: CIBC World Markets; PaineWebber Incorporated; SG Cowen




--------------------------------------------------------------------------------

Company Name: Arena Pharmaceuticals, Inc. Symbol: ARNA Exchange: Nasdaq

Filing Date: April 28, 2000 IPO Date: NA Offering Price : NA
Description: Though not a football team, Arena Pharmaceuticals likes the end-around. The company`s CART technology allows drug discovery without having to identify ligands, which trigger or suppress biological responses in organisms. The CART technology mimics the behavior of ligands to identify chemical compounds that alter biological
responses, facilitating faster drug discovery; CART is being targeted at treatments for obesity, various cancers, and other diseases. Arena is also developing an
Alzheimer`s disease treatment and an antifungal compound through subsidiary Aressa Pharmaceuticals. The firm has partnerships with Eli Lilly and Fujisawa
Pharmaceuticals. Director Michael Steinmetz owns almost 30% of Arena.

Underwriters: ING Baring; Prudential Vector Healthcare; SG Cowen




--------------------------------------------------------------------------------

Company Name: POZEN Inc. Symbol: POZN Exchange: Nasdaq

Filing Date: April 28, 2000 IPO Date: NA Offering Price : NA
Description: POZEN is a heady business. The development-stage company`s primary product candidates, MT 100 and MT 300, are being developed as oral and injectable
treatments, respectively, for migraine headaches. Other pharmaceutical products in the pipeline include MT 500, which blocks receptors in the brain that are implicated in
migraines, and MT 400, a migraine treatment that combines two commercially available drugs. The company has a licensing agreement with Hoffmann-La
Roche for MT 500 and plans to establish other such agreements with other pharmaceutical firms. CEO and Chief Scientist John Plachetka owns more than 20% of
POZEN.

Underwriters: U.S. Bancorp Piper Jaffray; Prudential Vector Healthcare; Pacific Growth Equities, Inc.




--------------------------------------------------------------------------------

Company Name: Argonaut Technologies, Inc. Symbol: AGNT Exchange: Nasdaq

Filing Date: April 27, 2000 IPO Date: NA Offering Price : NA
Description: Argonaut Technologies helps make compounds fit just right. The company makes instruments and reagents that chemists use for lead optimization and parallel
synthesis during pharmaceutical research. Its products include the Trident line of synthesizers, workstations, and sample processing stations; the Quest line for
mixing reaction solutions; and a variety of reagents. Argonaut targets the biotechnology, chemical research, life sciences, and pharmaceutical industries. The
company relies on collaborations with leading drugmakers -- such as Abbott Laboratories, Eli Lilly, Merck, and Pfizer -- to enhance new product design.
Shareholders include VC firms Kleiner Perkins (23%) and Institutional Venture Partners (20%).

Underwriters: Warburg Dillon Read LLC; ING Baring; SG Cowen




--------------------------------------------------------------------------------

Company Name: Genaissance Pharmaceuticals, Inc. Symbol: GNSC Exchange: Nasdaq

Filing Date: April 20, 2000 IPO Date: NA Offering Price : NA
Description: Genaissance Pharmaceuticals develops technologies to improve drug discovery and marketing based on population genomics, the analysis of genetic variations
within diverse populations. Its HAP Technology is being developed to examine haplotypes, units of genetic variation, in blood samples. Genetic information in
haplotypes is decoded using the DECOGEN Informatics System, after which the user can determine what sort of response a patient will have to a given drug.
Genaissance plans to market its product to drug developers and makers of drugs already on the market to identify patients most receptive to specific treatments.
The firm has collaborative and licensing agreements with Visible Genetics and Telik.

Underwriters: Deutsche Banc Alex. Brown; Bear, Stearns & Co. Inc.; Salomon Smith Barney; Warburg Dillon Read LLC




--------------------------------------------------------------------------------

Company Name: Pharsight Corporation Symbol: PHST Exchange: Nasdaq

Filing Date: April 17, 2000 IPO Date: NA Offering Price : NA
Description: Pharsight just might be the oracle of drug development. The company`s products and services help biotech and pharmaceutical firms build and shape their drug pipelines and decrease time and money spent on development. Using computer simulation, statistics, and data analysis along with pharmacology, disease and drug modeling,
genetics, and other databases, Pharsight helps clients determine drug-development targets, quickly develop new drugs, and weed out "no-go" candidates. Customers
include Johnson & Johnson (its largest client), AstraZeneca, Pfizer, and SmithKline Beecham. Through a partnership, directors Douglas Kelly and W. Ferrell
Sanders own more than 20% of Pharsight; McKesson HBOC owns nearly 20%.

Underwriters: Donaldson, Lufkin & Jenrette Securities Corporation; Chase H&Q; Wit SoundView; DLJdirect Inc.




--------------------------------------------------------------------------------

Company Name: Deltagen, Inc. Symbol: DGEN Exchange: Nasdaq

Filing Date: April 10, 2000 IPO Date: NA Offering Price : NA
Description: Mickey`s not the only one with a knockout mouse. Deltagen, a development-stage company, hopes its technology can generate, analyze, and study genetic
information more quickly than existing systems. Drug companies subscribe to its DeltaBase database of mammalian gene functions and use its DeltaSelect
target-validation program to select and validate drug-discovery targets. Using DeltaBase, Deltagen delivers knockout mice (in which the targeted gene function has been "knocked out") for drug-candidate testing. The firm has also developed Delta-GT that identifies the function of secreted proteins in mammals. Deltagen`s customers include Pfizer (64% of sales), Roche Biosciences, Merck, Schering-Plough, and Tularik.

Underwriters: Salomon Smith Barney; Robertson, Stephens & Company; U.S. Bancorp Piper Jaffray




--------------------------------------------------------------------------------

Company Name: Cepheid Symbol: CPHD Exchange: Nasdaq

Filing Date: April 7, 2000 IPO Date: NA Offering Price : NA
Description: Cepheid develops testing products for genetic profiling, DNA purification, the detection of food and water contaminants, and other applications. Product
candidates include the Smart Cycler, a DNA amplification (rapid duplication) and detection system for life science research, and the GeneXpert, a system
designed to extract and examine DNA from blood samples and spores and bacteria from water samples. The company has a collaborative agreement with Fisher
Scientific International to market the Smart Cycler upon its commercialization, and has formed a joint venture, Aridia, with Canadian company Infectio Diagnostic to
develop molecular diagnostic tests.


Underwriters: Warburg Dillon Read LLC; Prudential Vector Healthcare; Invemed Associates, Inc.




--------------------------------------------------------------------------------

Company Name: NEN Life Sciences, Inc. Symbol: NENL Exchange: Nasdaq

Filing Date: April 7, 2000 IPO Date: NA Offering Price : NA
Description: NEN Life Sciences provides research products and services worldwide to the biomolecular genomics field, which encompasses gene sequencing and gene-based
drug discovery. The company makes more than 1,500 products, including the MICROMAX line of reagent systems for gene expression analysis, the Kodak Image
Station for chemical imaging of protein and genetic material, and the FlashPlate Assay Platform, a system for drug-discovery and other assays. Research and
marketing partners of NEN include Eastman Kodak, AlphaGene, Merck, Affymetrix, and Motorola. Through management fund Genstar Capital, directors Jean-Pierre
Conte, Richard Hoskins, and Richard Paterson own more than 85% of the company.


Underwriters: Credit Suisse First Boston; ING Baring


--------------------------------------------------------------------------------

Company Name: Large Scale Biology Corporation Symbol: LSBC Exchange: Nasdaq

Filing Date: April 7, 2000 IPO Date: NA Offering Price : NA
Description: Tobacco to help cure cancer? That`s right: Large Scale Biology develops compounds from tobacco to treat non-Hodgkin`s lymphoma and other diseases. The
company uses its proteomic (the study of proteins) and genomic technologies for therapeutic, diagnostic, and drug-discovery research. Its GENEWARE technology
automatically inserts genes into organisms for analysis; its ProGEx system uses a database to identify protein compositions. Large Scale Biology derives revenue from
research collaborations with Dow Chemical (which accounts for nearly 90% of revenue) and from technology access fees. A partnership involving directors John Maki,
John O`Malley, and James TenBroek owns almost 30% of the company; Dow owns another 10%.

Underwriters: J.P. Morgan & Co.; Chase H&Q; William Blair & Company


--------------------------------------------------------------------------------

Company Name: Oculex Pharmaceuticals, Inc. Symbol: OCLX Exchange: Nasdaq

Filing Date: April 6, 2000 IPO Date: NA Offering Price : NA
Description: Here`s drug in your eye. Oculex Pharmaceuticals develops pharmaceuticals for ophthalmological conditions using its drug-delivery system, which enables
implantation of drugs in the eye. The company`s lead product candidates are Surodex, which treats eye inflammation following cataract surgery, and Posurdex,
for inflammation following vitreal and retinal surgeries. Other products in the works are targeted at glaucoma surgery, corneal transplant rejection, and various
post-surgical infections. Oculex has partnered with Bausch & Lomb to market Surodex and also has a research collaboration with Allergan. President Jerry Gin
and chief scientific officer Vernon Wong each own about 12% of Oculex; Transpac Capital owns 20%.

Underwriters: Warburg Dillon Read LLC; Banc of America Securities LLC; Dain Rauscher Wessels


--------------------------------------------------------------------------------

Company Name: Ista Pharmaceuticals, Inc. Symbol: ISTA Exchange: Nasdaq

Filing Date: April 5, 2000 IPO Date: NA Offering Price : NA
Description: Ista Pharmaceuticals has set its sights on developing pharmaceutical treatments for eye diseases. The company develops ophthalmic drugs based on
hyaluronidase, a naturally occurring enzyme. Its primary product candidate, Vitrase, is being developed to treat vitreous hemorrhaging, a condition in which blood leaks
into the fluid between the lens and the retina and obscures vision, and also for diabetic retinopathy, in which abnormal blood vessels in the back of the eye
impair vision. Other products in development include Keratase and Keraform, treatments for corneal diseases. Ista Pharmaceuticals has a worldwide marketing and
sales agreement with Allergan for Vitrase once it becomes commercialized.

Underwriters: CIBC World Markets; ING Baring; Prudential Vector Healthcare


--------------------------------------------------------------------------------

Company Name: Telik, Inc. Symbol: TELK Exchange: Nasdaq

Filing Date: April 3, 2000 IPO Date: NA Offering Price : NA
Description: Go Telik on the mountain: Telik (formerly Terrapin Technologies) discovers and develops small-molecule drugs, mainly for the treatment of cancer and diabetes.
The company uses its proprietary Target-Related Affinity Profiling (TRAP) technology to identify potential drug compounds by analyzing the way they interact with
proteins. Telik has research and development agreements with such companies as Sanwa Chemical Research Institute (a subsidiary of Japanese drug maker
Suzuken, 48% of sales), Sankyo, COR Therapeutics, and Scios. Telik`s investors include Alta V Management Partners (13%) and Sanwa (15%).

Underwriters: Warburg Dillon Read LLC; Chase H&Q; Legg Mason Wood Walker Incorporated


--------------------------------------------------------------------------------

Company Name: Illumina, Inc. Symbol: ILMN Exchange: Nasdaq

Filing Date: April 3, 2000 IPO Date: NA Offering Price : NA
Description: Illumina is here to enlighten. The company is developing instruments that measure genetic variation in individuals to devise new treatments for various diseases. Illumina`s main product, the BeadArray, facilitates multiple genetic assays by attaching microscopic beads to fiber-optic bundles; each bead holds a different molecule or DNA
sequence. The bundle is then dipped into a test sample, and a laser detects which beads reacted with the sample. Illumina is also developing the Oligator technology, which prepares DNA segments for BeadArray testing. Illumina collaborates with PE Biosystems, Dow Chemical, and Third Wave Technologies. Through the CW Group, director Charles Hartman owns 20% of the company.

Underwriters: Goldman, Sachs & Co.; Chase H&Q; SG Cowen


--------------------------------------------------------------------------------

Company Name: Kosan Biosciences Incorporated Symbol: KOSN Exchange: Nasdaq

Filing Date: March 31, 2000 IPO Date: NA Offering Price : NA
Description: Gene manipulation is the name of the game at Kosan Biosciences. The development-stage company alters naturally occurring polyketides to produce new classes
or improve upon existing classes of pharmaceuticals. Kosan has targeted six areas for its drug-development program: bacterial infections, gastrointestinal disorders,
mucus hypersecretion (a symptom of such conditions as asthma, cystic fibrosis, and allergies), cancer, immunosuppression, and nerve regeneration. The company is working with Johnson & Johnson subsidiary The R.W. Johnson Pharmaceutical Research Institute, Stanford University, and Harvard on its projects. CEO and co-founder Daniel Santi owns about 20% of the company.

Underwriters: Warburg Dillon Read LLC; CIBC World Markets; Prudential Vector Healthcare


--------------------------------------------------------------------------------

Company Name: Variagenics, Inc. Symbol: VGNX Exchange: Nasdaq

Filing Date: March 29, 2000 IPO Date: NA Offering Price : NA
Description: Variagenics uses pharmacogenomics, which studies links between genetic variability (measured in single nucleotide polymorphisms, or SNPs) and response to
drugs, to develop new drugs and diagnostic products. Products being developed include the Variagenic Impact Program, which analyzes SNP data to identify drug
targets, and the NuCleave DNA analysis platform, which performs assays on DNA samples to examine patients` responses to drugs. Initially focused on cancer, the
company is now also targeting cardiovascular, neurological, and inflammatory diseases. Variagenics has collaborative agreements with Covance and Quintiles
Transnational. The Sprout Group owns more than a fourth of the company.

Underwriters: Credit Suisse First Boston; Chase H&Q; SG Cowen


--------------------------------------------------------------------------------

Company Name: Versicor Inc. Symbol: VERS Exchange: Nasdaq

Filing Date: March 22, 2000 IPO Date: NA Offering Price : NA
Description: Versicor develops pharmaceuticals to treat fungal and bacterial infections. Its primary products, in clinical trials, are V-Echinocandin, which prevents cell wall formation in Candida and other infectious fungi; and V-Glycopeptide, an antibiotic to treat bacterial infections in hospital patients. Versicor plans to market these drugs directly to
hospitals. The company is also developing oxazolidinones, a new class of antibiotics, with Pharmacia & Upjohn, as well as deformylase inhibitors, which target unique enzymes in bacteria, with Novartis. BIOCOR, a partnership between Versicor and Biosearch Italia, develops new drug candidates. The firm`s investors include Schroders and HealthCare Investment Corporation.

Underwriters: Warburg Dillon Read LLC; Lehman Brothers; Pacific Growth Equities, Inc.


--------------------------------------------------------------------------------

Company Name: Advanced Medicine, Inc. Symbol: ADVM Exchange: Nasdaq

Filing Date: March 22, 2000 IPO Date: NA Offering Price : NA
Description: So how advanced are Advanced Medicine`s products? Its lead drug candidate, AMI-3817, potentially treats post-operative pain for up to 24 hours -- up to six times longer than the longest-acting drug available, bupivacaine. Targeting not only postoperative pain but also asthma, bacterial infection, neuropathic pain, and urinary incontinence, the development-stage firm discovers and develops multivalent small-molecule drug candidates. A multivalent compound can attach to several sites on a biological target, thereby improving such therapeutic properties as duration, potency, or safety. Advanced Medicine also plans to develop drug candidates using its multivalent technology in partnership with other biotech firms.

Underwriters: Goldman, Sachs & Co.; Merrill Lynch & Co.; Bear, Stearns & Co. Inc.


--------------------------------------------------------------------------------

Company Name: Ciphergen Biosystems, Inc. Symbol: CIPH Exchange: Nasdaq

Filing Date: March 21, 2000 IPO Date: NA Offering Price : NA
Description: Ciphergen Biosystems makes sure proteins aren`t forgotten while everyone`s off deciphering DNA. The company focuses on proteomics, or protein-based
research. Its ProteinChip System includes disposable ProteinChip arrays, a chip reader, and software that allows biologists and pharmaceutical developers to discover new protein biomarkers and to identify protein function by connecting DNA and protein research. The system can also analyze protein interactions. Customers include Amgen, Human Genome Sciences, and Merck. Ciphergen is also setting up Biomarker Discovery Centers, including one in California and another in Denmark. Investors in the company include Atlas Venture and laboratory services provider MDS.

Underwriters: SG Cowen; ING Baring; Warburg Dillon Read LLC


--------------------------------------------------------------------------------

Company Name: Rosetta Inpharmatics, Inc. Symbol: RSTA Exchange: Nasdaq

Filing Date: March 15, 2000 IPO Date: NA Offering Price : NA
Description: Rosetta Inpharmatics doesn`t provide clues to reading hieroglyphics -- it makes equipment and software for use in genomics, which involves analyzing genetic
information to identify gene functions and drug targets. Rosetta`s products include the Resolver Expression Data Analysis System, which stores and analyzes gene
expression data; FlexJet DNA microarrays, glass slides containing DNA sequences; and software libraries of various cell responses to genetic diseases and
treatments. The company has a strategic alliance with Agilent Technologies to make and market its products. Rosetta`s investors include Agilent, Olympic Venture
Partners, and Vulcan Ventures, a unit of Paul Allen`s Vulcan Northwest.

Underwriters: Warburg Dillon Read LLC; Lehman Brothers; Prudential Vector Healthcare


--------------------------------------------------------------------------------

Company Name: Genometrix Incorporated Symbol: GNMX Exchange: Nasdaq

Filing Date: March 15, 2000 IPO Date: NA Offering Price : NA
Description: Chips ahoy! Genometrix wants to put biotechnology and drug-discovery firms on the genomics fast track with its GenoVista services. The development-stage firm`s DNA chip microarrays allow for high-throughput analysis of genetic variation, gene expression profiling, and other data analysis (including plans for protein analysis) and
storage services. Genometrix is also building a DNA repository to license to its customers for genotyping analysis. Its customers include Schering-Plough, Procter
& Gamble, and the National Cancer Center. The firm has partnered with Motorola to develop DNA clinical systems. Founder, chairman, and CEO Mitchell Eggers owns
nearly 30% of the company; Motorola owns another 16%.

Underwriters: Lehman Brothers; Chase H&Q; Dain Rauscher Wessels; Thomas Weisel Partners LLC; Fidelity Capital Markets


--------------------------------------------------------------------------------

Company Name: Genomica Corporation Symbol: GNOM Exchange: Nasdaq

Filing Date: March 15, 2000 IPO Date: NA Offering Price : $15.00 to $17.00
Description: Bringing genomics discoveries to the masses is Genomica`s mission. The company develops and sells bioinformatics software for biotechnology and
pharmaceutical companies. Its Discovery Manager suite allows customers involved in epidemiology, molecular biology, pharmacogenomics, and clinical, statistical, and
human genetics to examine DNA sequences, isolate and analyze DNA variations, and build and compare genetic maps. Customers include AstraZeneca, Glaxo
Wellcome, Orchid BioSciences, and Warner-Lambert. The company has partnered with PE Biosystems to develop hardware and software suites. Genomica`s
investors include The Kaufmann Fund, AMVESCAP, and ARCH Venture Partners.

Underwriters: CIBC World Markets; Dain Rauscher Wessels; Prudential Vector Healthcare


--------------------------------------------------------------------------------

Company Name: Pain Therapeutics, Inc. Symbol: PTIE Exchange: Nasdaq

Filing Date: March 13, 2000 IPO Date: NA Offering Price : NA
Description: Pain Therapeutics is providing opiates for the masses. The development-stage company is creating less addictive painkillers by combining an opioid (such as
morphine) with an opioid antagonist (such as naloxone), thus improving the drug`s performance and decreasing its side effects. Pain Therapeutics has four drugs in clinical
trials that could treat everything from severe cancer pain to the chronic pain associated with arthritis. Because the drug candidates contain FDA-approved components, the
firm hopes for quicker approval. Founder and CEO Remi Barbier owns nearly 40% of the company; other investors include TVM Techno Venture Management and Sanford
Robertson, founder of Robertson Stephens.

Underwriters: Robertson, Stephens & Company; CIBC World Markets; Lazard Freres & Co. LLC


--------------------------------------------------------------------------------

Company Name: NetGenics, Inc. Symbol: NTGC Exchange: Nasdaq

Filing Date: March 13, 2000 IPO Date: NA Offering Price : $11.00 to $13.00
Description: NetGenics helps life sciences companies net more discoveries from their research. The development-stage bioinformatics company produces the SYNERGY
software system, which allows researchers to integrate disparate databases of information generated from gene expression research, single nucleotide polymorphism
(SNP) mapping, and other scientific data. The software is installed on a company`s intranet for better security. The firm also provides consulting services. NetGenics`
customers include American Home Products, Pfizer, and Aventis. The company also has alliances with IBM and Incyte Pharmaceuticals, which is also an investor in
NetGenics. Other investors include Venrock Associates and Oxford Bioscience Partners.

Underwriters: Chase H&Q; Warburg Dillon Read LLC


--------------------------------------------------------------------------------

Company Name: Packard BioScience Company Symbol: PBSC Exchange: Nasdaq

Filing Date: March 8, 2000 IPO Date: NA Offering Price : NA
Description: Packard BioScience makes and markets instruments for the life science and nuclear industries. Subsidiary Packard Instruments makes imaging systems,
laboratory robotics, and bioanalytical instruments for drug discovery and screening procedures; the unit also markets genomics analysis and other products, including
a biochip developed at the Engelhardt Institute of Molecular Biology in Moscow. Customers include major biotech and pharmaceutical firms. Through Canberra
Industries, Packard also makes instruments to detect and monitor radioactivity for clients such as the US Department of Energy and the Tennessee Valley
Authority. Investment firm Stonington Partners owns about 60% of the company.


Underwriters: Merrill Lynch & Co.; Chase H&Q; Robert W. Baird & Co. Incorporated; Banc of America Securities LLC; Thomas Weisel Partners LLC


--------------------------------------------------------------------------------

Company Name: Transgenomic, Inc. Symbol: TBIO Exchange: Nasdaq

Filing Date: March 10, 2000 IPO Date: NA Offering Price : $12.00 to $14.00
Description: Mutants can`t hide from Transgenomic. The firm`s WAVE System -- which includes a separation column, proprietary software, and reagents and other
consumables -- allows researchers to quickly identify DNA mutations (known as single nucleotide polymorphisms, or SNPs). Customers include such institutions as Harvard University and the National Institutes of Health and companies like SmithKline Beecham. Transgenomic plans to develop similar systems to analyze RNA, amino acids, and other
structures. Founded in 1985 as CETAC Technologies, a maker of nebulizers, the company grew via acquisitions and became Transgenomic in 1997. Founder Collin
D`Silva and his father Arthur will own about 30% of Transgenomic after the IPO.

Underwriters: Chase H&Q; Bear, Stearns & Co. Inc.; Dain Rauscher Wessels


--------------------------------------------------------------------------------

Company Name: Stratagene Holding Corporation Symbol: STGN Exchange: Nasdaq

Filing Date: March 10, 2000 IPO Date: NA Offering Price : NA
Description: Stratagene takes biotech development to the next level. Founded in 1984 by former Scripps Foundation scientist Joseph Sorge, the company makes reagents, kits, and cell-derived products (nearly 60% of sales), nucleic acid purification and analysis products, and gene-sequencing software and analysis tools. Subsidiary Biocrest, which
makes reagents, owns a 49% stake in Cenetron Diagnostics, which uses reagents to test DNA and RNA samples for disease (it has a contract with the City of
Austin, Texas, to perform HIV testing). The company has offices in California and a manufacturing facility in Texas. Sorge owns three-fourths of the company.

Underwriters: Merrill Lynch & Co.; Salomon Smith Barney; Dain Rauscher Wessels; Prudential Vector Healthcare


--------------------------------------------------------------------------------

Company Name: deCODE genetics, Inc. Symbol: DCGN Exchange: Nasdaq

Filing Date: March 8, 2000 IPO Date: NA Offering Price : NA
Description: deCODE genetics gets into Icelanders` genes. Under a license granted by Iceland`s government, the company is creating a database from the medical records and
genetic information of the population of that country, which has remained relatively unchanged since the ninth century. deCODE is also developing a database to
cross-reference the data and plans to market both databases and other bioinformatics software products. It is also seeking the genetic sources of various diseases.
The company has a research contract with Hoffmann-La Roche and alliances with Affymetrix and others. deCODE genetics was founded in 1996 by Kari Stefansson.
Investors in the company include Roche, Atlas Venture, and Polaris Venture Partners.

Underwriters: Morgan Stanley Dean Witter; Lehman Brothers


--------------------------------------------------------------------------------

Company Name: Cellomics, Inc. Symbol: CLMX Exchange: Nasdaq

Filing Date: March 3, 2000 IPO Date: NA Offering Price : NA
Description: Cellomics makes cell study simpler. The company`s instruments, assays, reagents, and software products allow biotechnology and drug-discovery companies to
analyze cells quickly, including the way potential drugs interact with living cells. Its automated ArrayScan system analyzes cells on microplates using fluorescence imaging; it is developing the more advanced CellChip system with ACLARA BioSciences. Cellomics is also developing optical screening systems with German optics firm Carl Zeiss and markets products made by a Zeiss subsidiary. Cellomics has alliances with Johnson & Johnson, Merck, and Warner-Lambert. InterWest Partners, Axiom Venture Partners, and Delphi Ventures own stakes in Cellomics.

Underwriters: Prudential Vector Healthcare; ING Baring; Dain Rauscher Wessels


--------------------------------------------------------------------------------

Company Name: Inspire Pharmaceuticals, Inc. Symbol: ISPH Exchange: Nasdaq

Filing Date: February 25, 2000 IPO Date: NA Offering Price : NA
Description: Inspire Pharmaceuticals won`t leave a dry eye in the house. The company develops drugs to treat various respiratory and ocular diseases (including dry eye)
caused by improper functioning of P2Y receptors, which regulate the body`s mucosal hydration and clearance. The company`s lead products are in clinical trials to treat
dry eye, chronic bronchitis, and cystic fibrosis. Other products in Inspire`s pipeline target sinusitis, retinal detachment, and the diagnosis of lung diseases. Inspire
Pharmaceuticals has collaborative agreements with Genentech, Kissei Pharmaceuticals, and Santen Pharmaceuticals. Inspire`s investors include Polaris Venture Partners, Domain Associates, and InterWest Partners, among others.

Underwriters: Bear, Stearns & Co. Inc.; Deutsche Banc Alex. Brown; U.S. Bancorp Piper Jaffray


--------------------------------------------------------------------------------

Company Name: AtheroGenics, Inc. Symbol: AGIX Exchange: Nasdaq

Filing Date: February 25, 2000 IPO Date: NA Offering Price : NA
Description: AtheroGenics is developing small-molecule drugs for the treatment of such chronic inflammatory diseases as atherosclerosis (clogging of the arteries), asthma, and
rheumatoid arthritis. The company`s products prevent the production of inflammatory proteins; its lead product, AGI-1067, is in trials as a treatment for restenosis (the
reclosure of arteries after angioplasty). AtheroGenics has identified other compounds that may be used to treat cystic fibrosis and organ transplant rejection.
Schering-Plough is helping to develop AGI-1067. Founded in 1993 by Emory University scientist Russell Medford, AtheroGenics` investors include William Blair &
Company and Sprout Group; the company intends to go public.

Underwriters: SG Cowen; Chase H&Q; Adams, Harkness & Hill, Inc.; A.G. Edwards & Sons, Inc.


--------------------------------------------------------------------------------

Company Name: Esperion Therapeutics Inc. Symbol: ESPR Exchange: Nasdaq

Filing Date: February 24, 2000 IPO Date: NA Offering Price : NA
Description: Esperion Therapeutics develops drugs that spirit cholesterol from clogged arteries. Co-founded by Roger Newton (who helped discover and develop Lipitor at
Warner-Lambert), Esperion`s drug candidates include ProApoA-I (helps clear blocked arteries), ApoA-I Milano (helps clear arteries and prevent them from closing after
balloon angioplasty), and large unilamellar vesicles (LUVs), which cycle through the body to remove cholesterol. Esperion Therapeutics is also developing treatments for such metabolic diseases as diabetes and obesity. The company plans to partner with other drug firms to make and sell its products once they are approved. Oak Investment Partners and TL Ventures each own about 25% of the company.

Underwriters: Robertson, Stephens & Company; Chase H&Q; U.S.Bancorp Piper Jaffray


--------------------------------------------------------------------------------

Company Name: ViroLogic, Inc. Symbol: VLGC Exchange: Nasdaq

Filing Date: February 22, 2000 IPO Date: NA Offering Price : NA
Description: ViroLogic`s products are persuasive when it comes to making treatment choices. By measuring the drug resistance of particular virus mutations, the company`s
PhenoSense assays allow doctors to choose the right drug for each individual. ViroLogic`s lead product, PhenoSense HIV, tests the resistance of a patient`s strain of HIV to existing antiviral treatments; the company is developing PhenoSense assays for hepatitis B and C as well. ViroLogic`s assays employ a fast version of phenotypic testing, which is considered more reliable than genotypic testing, which cannot detect certain viral mutations. BB BIOTECH AG, a publicly traded Swiss biotech investment firm, owns more than
one-fourth of the company.

Underwriters: CIBC World Markets; ING Baring; Prudential Vector Healthcare


--------------------------------------------------------------------------------

Company Name: Signal Pharmaceuticals, Inc. Symbol: SGNL Exchange: Nasdaq

Filing Date: February 18, 2000 IPO Date: NA Offering Price : NA
Description: Signal Pharmceuticals wants to be the traffic cop for disease. The drug discovery company is identifying drugs that regulate genes and the production of
disease-causing proteins. The company maps gene-regulating pathways in cells in an effort to identify molecular targets that activate or deactivate genes. By identifying these genes, the company hopes to develop treatments that can selectively regulate their activation. Signal`s drug discovery programs target inflammatory, cardiovascular, and neurological diseases, as well as cancer. The company, which is going public, has collaborative discovery agreements with such companies as Nippon Kayaku, DuPont Pharmaceuticals, and Axys Pharmaceuticals.

Underwriters: Robertson, Stephens & Company; Chase H&Q; CIBC World Markets


--------------------------------------------------------------------------------

Company Name: Paradigm Genetics, Inc. Symbol: PDGM Exchange: Nasdaq

Filing Date: February 18, 2000 IPO Date: NA Offering Price : NA
Description: Would you like mustard with that? Paradigm Genetics uses its high-throughput GeneFunction Factory on such model organisms as Arabidopsis (a plant in the mustard family) to determine the functions of specific genes, mainly for agricultural purposes. The company`s GeneFunction Factory uses an assembly-line approach
to discovering gene functions, while its FunctionFinder bioinformatics database is a repository for what is discovered. Paradigm`s sales come from agreements with Bayer (to develop herbicides) and Monsanto (to develop crop production and nutrition products) and a grant from the US Department of Energy. Polaris Venture Partners, Intersouth Partners, and Burrill & Company together own about half the company.

Underwriters: Chase H&Q; J.P. Morgan & Co.; Pacific Growth Equities, Inc.; Stephens Inc.


--------------------------------------------------------------------------------

Company Name: Orchid BioSciences, Inc. Symbol: ORCH Exchange: Nasdaq

Filing Date: February 18, 2000 IPO Date: NA Offering Price : NA
Description: Orchid BioSciences develops technologies to enhance genetic research. Its Genetic Bit Analysis (GBA) technology focuses on single nucleotide polymorphisms
(SNPs), substances within DNA that indicate genetic diversity, to enhance drug discovery and efficacy. Its primary product, the SNPstream system, has been designed to search for specific SNPs on strands of DNA, identifying possible sites for drug interactions. The company also sells consumable testing kits and high-throughput SNP scoring services. Orchid BioSciences` GeneScreen subsidiary provides forensic and paternity genetic testing. The company has collaborative agreements with Affymetrix and Sarnoff
Corporation to develop more GBA applications.

Underwriters: Credit Suisse First Boston; Robertson, Stephens & Company; Salomon Smith Barney


--------------------------------------------------------------------------------

Company Name: First Horizon Pharmaceutical Corporation Symbol: INGN Exchange: Nasdaq

Filing Date: February 18, 2000 IPO Date: NA Offering Price : $12.00 to $14.00
Description: First Horizon Pharmaceutical buys and licenses off-patent and other drugs divested by larger companies. The company`s drug portfolio includes Nitrolingual, an
angina treatment; Robinul, a peptic ulcer treatment; and Tanafed for allergy and cold symptoms. First Horizon has also partnered with Penwest Pharmaceuticals to develop
a treatment for migraines. The company does not make the products it sells; instead, it has manufacturing agreements with all companies whose products it acquires, including American Home Products and Aventis. Major customers include McKesson HBOC, Cardinal Health, and Bergen Brunswig. Chicago-area biotech investor John Kapoor will own more than half of First Horizon after the IPO.

Underwriters: Robertson, Stephens & Company; Banc of America Securities LLC; Chase H&Q


--------------------------------------------------------------------------------

Company Name: Introgen Therapeutics, Inc. Symbol: INGN Exchange: Nasdaq

Filing Date: February 17, 2000 IPO Date: NA Offering Price : NA
Description: Introgen Therapeutics` gene-therapy products fight cancer by attempting to restore or correct missing or aberrant gene functions. Its flagship product, INGN 201, is being developed in collaboration with Aventis and is in Phase III trials for effectiveness against head and neck cancers. Introgen is also researching genetic products for treating
breast, lung, colorectal, prostate, and other cancers. The company has established a presence in Europe through subsidiary Gendux AB to enhance its connections there.
Introgen has a research agreement with the National Cancer Institute to conduct clinical studies of INGN 201. Aventis owns about 25% of the company.

Underwriters: SG Cowen; Prudential Vector Healthcare


--------------------------------------------------------------------------------

Company Name: Genomic Solutions Inc. Symbol: GNSL Exchange: Nasdaq

Filing Date: February 11, 2000 IPO Date: NA Offering Price : NA
Description: Genomic Solutions develops and makes instruments and software to analyze gene activity (expression) and to isolate and identify proteins. Its lead product, the
GeneTAC Biochip System, uses biochips (DNA fragments attached to glass) to compare gene expression in diseased and normal cells. Genomic Solutions also makes the Investigator Proteomic System, which separates and identifies proteins, and software to integrate and store data collected by its products. Genomic Solutions`s customers include
Merck, Monsanto, and Biogen. Chase Capital Partners owns about 30% of the firm, but scientific instruments maker PerkinElmer has a right to purchase the company
outright after it goes public, as Genomic plans.

Underwriters: Warburg Dillon Read LLC; Dain Rauscher Wessels; Punk, Ziegel & Company


--------------------------------------------------------------------------------

Company Name: Sangamo BioSciences, Inc. Symbol: SGMO Exchange: Nasdaq

Filing Date: February 11, 2000 IPO Date: NA Offering Price : NA
Description: Sangamo BioSciences hopes zinc fingers have the Midas touch when it comes to regulating gene expression. The company`s zinc finger DNA binding
proteins (ZFPs) control gene expression (activation) and cell function. Sangamo markets its Universal Gene Recognition platform of ZFPs to the drug discovery,
agricultural, biotechnology, and other industries to aid in the development of new drugs, seeds, fertilizers, and other compounds. The company has collaborative
agreements with such companies as AstraZeneca, Glaxo Wellcome, DuPont, and Johnson & Johnson. Founder and CEO Edward Lanphier II owns about 25% of
the company; JAFCO of Japan and Lombard Odier & Cie. of Switzerland each own another 15%.

Underwriters: Lehman Brothers; Chase H&Q; ING Baring; William Blair & Company


--------------------------------------------------------------------------------

Company Name: Lexicon Genetics Incorporated Symbol: LEXG Exchange: Nasdaq

Filing Date: February 9, 2000 IPO Date: NA Offering Price : NA
Description: Lexicon Genetics is a real knockout. The genomics company discovers genes, then makes information about them available by selling subscriptions to its OmniBank
and other databases. Lexicon also develops and sells cloned mice with specific genes knocked out ("knockout mice"). The company sells its genetic information to drug
discovery firms; collaborators include Millennium Pharmaceuticals and Merck. Through "e-Biology" agreements with drug companies, universities, and other organizations, Lexicon hopes to earn royalties from drugs developed using its databases. Director Gordon Cain (whose Sterling Group conducted chemical company buyouts in the 1980s) owns more than 40% of the company, which is going public.

Underwriters: J.P. Morgan & Co.; Credit Suisse First Boston; Dain Rauscher Wessels; Punk, Ziegel & Company


--------------------------------------------------------------------------------

Company Name: PRAECIS PHARMACEUTICALS INCORPORATED Symbol: PRCS Exchange: Nasdaq

Filing Date: February 8, 2000 IPO Date: NA Offering Price : $12.00 to $14.00
Description: PRAECIS PHARMACEUTICALS hopes its peptide-based drugs will be the precise answer to diseases aggravated by hormones. Its product abarelix-depot-M is being developed to halt prostate cancer growth by dropping patients` testosterone immediately. A similar drug, abarelix-depot-F (both are in clinical trials), is also being
developed to treat endometriosis in women by lowering estrogen levels. Other drugs in PRAECIS`s pipeline target Alzheimer`s disease and muscle pain. The company has collaborative agreements with Amgen and Sanofi-Synthelabo to distribute abarelix worldwide upon its commercialization. Citing a poor market for biotech stocks, PRAECIS withdrew a planned IPO in 1998.

Underwriters: Salomon Smith Barney; CIBC World Markets; Credit Suisse First Boston


--------------------------------------------------------------------------------

Company Name: Adolor Corporation Symbol: ADOR Exchange: Nasdaq

Filing Date: February 8, 2000 IPO Date: NA Offering Price : $12.00 to $14.00
Description: If you haven`t got time for the pain, or the side effects brought on by painkillers, Adolor wants to help. In keeping with the movement toward better pain
management (doctors, loath to attract the attention of government drug officials, have until recently underprescribed opiates to cancer patients and others in extreme pain), the company is developing better pain palliatives. One of Adolor`s drugs is used with narcotics to reduce such side effects as bowel dysfunction and nausea and allow administration of higher doses of painkiller. Adolor is also developing treatments for inflammatory pain, itch, and visceral pain. The company has three drug candidates in clinical trials; others are in
the research stage.

Underwriters: Warburg Dillon Read LLC; Robertson, Stephens & Company; Pacific Growth Equities, Inc.


--------------------------------------------------------------------------------

Company Name: Exelixis, Inc. Symbol: EXEL Exchange: Nasdaq

Filing Date: February 7, 2000 IPO Date: NA Offering Price : NA
Description: We`ve come a long way, baby, but we still have a lot in common with the fruit fly. Formerly known as Exelixis Pharmaceuticals (Exelixis is Greek for evolution), the
company uses model organisms, such as fruit flies and roundworms, to gather and compare genetic data aimed at speeding the development of drugs, insecticides, and
animal health products. Exelixis` minority-owned affiliate, German biotech ARTEMIS Pharmaceuticals, performs similar testing on mice and zebra fish. The company has
an agricultural biotech joint venture, GenOptera, with Bayer and collaborative deals with Pharmacia & Upjohn and Bristol-Myers Squibb. Investors in Exelixis include
Atlas Venture and Oxford Bioscience Partners.

Underwriters: Goldman, Sachs & Co.; Credit Suisse First Boston; SG Cowen


--------------------------------------------------------------------------------

Company Name: Rigel Pharmaceuticals, Inc. Symbol: RIGL Exchange: Nasdaq

Filing Date: February 4, 2000 IPO Date: NA Offering Price : NA
Description: When immune systems attack, Rigel Pharmaceuticals wants to be there. Rigel develops small-molecule drugs, and has identified nine drug candidates for asthma,
allergy, transplant rejection, tumors, and such autoimmune conditions as rheumatoid arthritis and inflammatory bowel disease. The company uses retroviruses to induce a disease-like response in cells, allowing for easier identification of targets for drug discovery. All of its products are in preclinical stages. Rigel has collaborations with Cell Genesys, Johnson & Johnson`s, Neurocrine Biosciences, Novartis, and Pfizer. Novartis and Johnson & Johnson own 7% and 6%, respectively, of Rigel, which is going public.

Underwriters: Warburg Dillon Read LLC; Robertson, Stephens & Company; Prudential Vector Healthcare


--------------------------------------------------------------------------------

Company Name: DrugAbuse Sciences, Inc Symbol: DASI Exchange: Nasdaq

Filing Date: February 3, 2000 IPO Date: NA Offering Price : NA
Description: DrugAbuse Sciences can help if you`re addicted to more than love. The development-stage company is working on timed-release drug and alcohol addiction treatments that can be administered monthly by health professionals rather than daily by addicts incapable of long-term compliance. Its NALTREL (based on naltrexone, which
blocks the neural receptors that produce a heroine or alcohol high) is in clinical trials. Other receptor blocks are in the works, along with versions of methadone and
overdose treatments. The company was founded in 1993 by chairman and CEO Philippe Pouletty (also founder of SangStat Medical), who owns 24% of the company.
Venture capital firm Partech International owns 13%.

Underwriters: Warburg Dillon Read LLC; Robertson, Stephens & Company


--------------------------------------------------------------------------------

Company Name: Tanox, Inc. Symbol: TNOX Exchange: Nasdaq

Filing Date: February 2, 2000 IPO Date: NA Offering Price : NA
Description: Tanox develops monoclonal antibodies, which mimic the human immune system`s defenses, to treat immunologic and infectious diseases and cancer. The company`s
leading product, E25, is being tested to treat allergic asthma and hay fever by blocking allergic reactions. Other products in the pipeline include HU-901, designed
to alleviate allergic reactions to peanuts, and 5D12, designed to treat autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company has collaborative agreements with Novartis and Genentech to commercialize and market E25; other collaborative partners include Chiron and Biogen. Novartis owns about 20% of Tanox; co-founders Nancy and Tse Wen Chang (divorced) own another 20%.

Underwriters: CIBC World Markets; Robertson, Stephens & Company; Warburg Dillon Read LLC; Adams, Harkness & Hill, Inc.; KBC Securities, Inc.


--------------------------------------------------------------------------------

Company Name: InterMune Pharmaceuticals, Inc. Symbol: ITMN Exchange: Nasdaq

Filing Date: February 2, 2000 IPO Date: NA Offering Price : $14.00 to $16.00
Description: Orphan drugs for sick children? InterMune hopes so. InterMune Pharmaceuticals has licensed Actimmune (interferon gamma-1b) from its former parent Connetics
(which in turn had licensed it from top biotech Genentech) for diseases that primarily affect children. It currently markets Actimmune for chronic granulomatous disease, an immune system disease, and is developing applications for osteopetrosis, idiopathic pulmonary fibrosis, systemic fungal infections, and cystic fibrosis. The company is also developing anti-infective drugs to treat staph and other infections. Biotech firm Connetics spun out InterMune in 1999; investors include Sanderling Ventures and Warburg Pincus.

Underwriters: Warburg Dillon Read LLC; Chase H&Q; Prudential Vector Healthcare


--------------------------------------------------------------------------------

Company Name: IntraBiotics Pharmaceuticals, Inc. Symbol: IBPI Exchange: Nasdaq

Filing Date: January 27, 2000 IPO Date: NA Offering Price : NA
Description: In a manner of speaking, IntraBiotics Pharmaceuticals is developing a cure for the common plague. The company develops antibiotics and antifungals for fighting such serious infections as vancomycin-resistant enterococci (VRE), a deadly strain of bacteria that can infect patients with weakened immune systems, primarily in hospitals.
Its drug candidate Ramoplanin Oral is being developed to eliminate VRE from the intestines of patients who are most at risk of infection. IntraBiotics is also developing
Protegrin IB-367 Rinse to reduce painful mouth ulcers common in cancer therapy patients. The company licenses antibiotic candidates from universities and other
pharmaceutical companies.

Underwriters: Deutsche Banc Alex. Brown; Warburg Dillon Read LLC; SG Cowen; Adams, Harkness & Hill, Inc.


--------------------------------------------------------------------------------

Company Name: Allos Therapeutics, Inc. Symbol: ALTH Exchange: Nasdaq

Filing Date: January 26, 2000 IPO Date: NA Offering Price : NA
Description: Allos Therapeutics is developing small-molecule drugs that increase the amount of oxygen released from red blood cells. Its primary product, RSR13, makes solid tumors more susceptible to radiation therapy. (Poorly oxygenated cancer cells are resistant to radiation.) Allos plans to market RSR13 directly to radiation therapists in
the US. The company is also devising other applications for RSR13, including improved treatments for cardiovascular diseases and strokes; it will seek licensing agreements with other pharmaceutical firms to market the product to these sectors. Investors in Allos include Oak Investment Partners, Sprout Group (an affiliate of Donaldson, Lufkin & Jenrette), and Johnson & Johnson.

Underwriters: SG Cowen; Prudential Vector Healthcare; U.S. Bancorp Piper Jaffray


--------------------------------------------------------------------------------

Company Name: Sequenom, Inc.. Symbol: SQNM Exchange: Nasdaq

Filing Date: November 24, 1999 IPO Date: January 24, 2000 Offering Price : $23 to $25
Description: Gene sequencing is no dream sequence for Sequenom. The company seeks to shed light on the genetic underpinnings of life for uses in industrial genomics.
Sequenom`s MassArray technology uses mass spectrometry to analyze variations in DNA (the most common are called single nucleotide polymorphisms) to
determine which ones have an impact on human health, agricultural yields, or livestock production. The company`s Genolyzer software analyzes genotype
samples. Its SpectroCHIP silicon wafers are used with the MassArray system to analyze biomolecules. Sequenom is beta testing its technology at Genzyme,
the US Department of Agriculture, and the National Institutes of Health, among others.

Underwriters: Warburg Dillon Read LLC; Robertson, Stephens & Company; SG Cowen


--------------------------------------------------------------------------------

Company Name: ACLARA BioSciences, Inc. Symbol: ACLA Exchange: Nasdaq

Filing Date: January 20, 2000 Offering Price : NA
Description: ACLARA BioSciences pioneered lab-on-a-chip technology, which uses electric fields to move fluids through channels on a microchip. The company (formerly
Soane BioSciences) is developing microfluidic and microfabrication products for use in genomic (DNA- and RNA-related) and pharmaceutical research. ACLARA
BioSciences has formed development alliances with PE Biosystems, whose parent company (PE Corporation) owns 11% of ACLARA, and with Johnson & Johnson,
which owns 10%. Venture capital firm Ampersand Ventures also owns 19% of the company, whose operations are primarily in the US.

Underwriters: Deutsche Bank Securities; Warburg Dillon Read LLC; U.S. Bancorp Piper Jaffray


--------------------------------------------------------------------------------

This listing is not an offer to sell nor a solictation of offers to buy any of the securities mentioned herein. The information contained in this website has been obtained from sources considered reliable, but we do not guarantee that the material is accurate or complete. Investors are advised to review the prospectus with and investment professional before making an investment decision.

[ricox]

@ ohrenschützer

Hast Du auch schon mal in Deine Betrachtungen mit einbezogen, daß einige Deiner genannten Biotechs noch diesen Monat zum Ende Ihrer lock-up-Periode kommen? Das heißt ja meist nichts gutes. Diesen Monat wäre ich Exelixis voll in die Scheiße getreten, wenn ich 2 Tage früher gekauft hätte. Schau Dir mal den Absturz nach dem Ende der lock-up an.
Meinst Du nicht, daß es den anderen nicht genauso gehen könnte?

Gruß,
ricox

[Piddy]

hey
endlich mal bio ipo`s.
ich trade zum grossen teil nur mit bio ipo`s.diese danken es meist mit
einer enormen performance,aber auch mit extremen risiko.
aber,das risiko hat sich jetzt auch auf die grossen der branche ver-
lagert.beispiele gab es in letzter zeit genug.bei den mini/midi caps
muss man immer am ball bleiben und hoellisch aufpassen.aber mit den
heutigen informationsquellen und einem stopp loss hat man 2 gute werk-
zeuge in der hand.
die lock up frist ist gut geeignet ein unternehmen evtl.noch besser
einschaetzen zu koennen.viele verkaeufe nach lu frist sollten einem
dann zu denken geben.das schoene bei den amis ist,das man alles nach-
vollziehen kann,z.b.wer wieviel verkauft hat.
sicher sind die versager,wie in anderen branchen auch,uebergewichtet,
aber eine von dreien gibt auch schon eine gute performance.
ich liste mal einige aussichtsreiche bio`s auf:
gnt-genstar therapeutic
sgmo-sangamo bio---3 strong buy---900 mill.mkt.cap.
gene-genome therapeutics---1 strong buy---500 mill.mkt.cap.
tnox-tanox---1 strong buy/1 buy---1,5 mrd.mkt.cap.
arna-arena pharmaceuticals---3 strong buy---950 mill.mkt.cap.
ilxo-ilex oncology---3 strong buy/3 buy---750 mill.mkt.cap.
cbst-cubist pharmaceuticals---3 strong buy---1,4 mrd.mkt.cap.
absc-aurora bioscience---3 strong buy/3 buy---1,4 mrd.mkt.cap.
gnsc-genaissance pharmaceuticals---5 strong buy
itmn-intermune pharmaceuticals
(es sind auch nicht ipo`s dabei,glaub ich)
die blockbuster ag:-tanox-allergisches asthma-zulassungsbescheid von
der FDA 1Q 2001.ein milliarden medikament.
die darlings der fonds/analysten:arena pharma.-genaissence pharma.
untersucht diese beiden,und ihr werdet mir evtl.recht geben.
intermune hat sich in den letzten negativen wochen recht gut gehalten.
wenn ihr auch einige vorschlaege haben solltet,immer her damit.
gruss,piddy

[ohrenschützer]

wie gesagt, ich hatte pdgm, gnsl und allos. sind jedoch alle durch den schlecht gwählten kaufzeitpunkt durch stopp-loss rausgeflogen.

ich favoritisiere sgmo,orch,lexg und gnsc.
mit dem ende der lockup-frist hast du natürlich ein gutes kontrollelement.
nur wenn du infos über solche firmen haben willst ist es meisten auf englich und mit bio-vokabular durchsetzt.was für mich heisst das ich meistens null verstehe.
was ich euch empfehlen kann ist der medved quote tracker.(hat mir jemand in einem anderen board empfohle)
das ist ne software zum runterladen (kostenlos)in die du dann deine ganzen werte in der art einer watschlist einträgst, die dann teils realtime teils verzögerter kurse bis zu aller 2 sec erneuert werden.
es bietet aber noch ne menge zusatztools für techniche analyse und auch einen info teil wo alle zu der firma bekannten news(von über 200 web sites) aufgeührt werden.
hier, bei rangingbull, siliconinvestor und bigcharts hol ich mir dann all meine news.oft las ich es mir auch übersetzen von alta-vista.com unter link translate doch da kommt oft nur scheiße bei raus.

eigentlich müsste es für dieses segment doch so was wie einen fond geben. ich hab schon von ipo fonds gehört, aber keinem der sich auf biotech emmisionen spezialisiert und ich klaub kaum das piquet(oder wie sich das schimpft)oder andere einen großen anteil in diesem segment haben.

als ist mann mal wieder auf sich selbt gestellt.

ciau
ohrenschützer

[Piddy]

hey
wenn du fonds suchen willst,dann schau mal unter
www.nasdaq.com
nach.
riesenauswahl und sehr gute ausfuehrung.
gruss,piddy